TD Capital Management’s PacWest Bancorp PACW Stock Holding History

TD Capital Management’s Portfolio PACW Stock Details PACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-98	Closed	-$778	–	438
2023 Q3	$778	Hold	98	–	–	﹤0.01%	387
2023 Q2	$800	Hold	98	–	–	﹤0.01%	392
2023 Q1	$954	Buy	98 +1	+1%	+$22	﹤0.01%	384
2022 Q4	$2.23K	Buy	97 +1	+1%	+$24	﹤0.01%	332
2022 Q3	$2K	Buy	+96	New	+$2.58K	﹤0.01%	329
2022 Q1	–	Sell	-94	Closed	-$4K	–	371
2021 Q4	$4K	Hold	94	–	–	﹤0.01%	328
2021 Q3	$4K	Buy	94 +1	+1%	+$41	﹤0.01%	310
2021 Q2	$4K	Buy	+93	New	+$3.98K	﹤0.01%	302
2020 Q1	–	Sell	-1,210	Closed	-$46K	–	287
2019 Q4	$46K	Hold	1,210	–	–	0.01%	121
2019 Q3	$44K	Hold	1,210	–	–	0.01%	119
2019 Q2	$47K	Buy	+1,210	New	+$46.8K	0.01%	101

Other funds holding PACW

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

TD Capital Management's PACW Position: Q4 2023 in Review

TD Capital Management sold out of PacWest Bancorp (PACW) in Q4 2023, closing a stake of 98 shares — an estimated $778 sold.

TD Capital Management first reported a position in PACW in Q2 2019 and held it in 11 quarters. The position peaked at $47K in Q2 2019. 4 funds tracked by Wall St. Rank hold PACW as of Q4 2023.

TD Capital Management reported no remaining PacWest Bancorp position as of Q4 2023 after selling out during the quarter.
TD Capital Management sold 98 PacWest Bancorp shares in Q4 2023, an estimated $778.
TD Capital Management first reported a position in PacWest Bancorp in Q2 2019 and held it in 11 quarters.
TD Capital Management's PacWest Bancorp position peaked at $47K in Q2 2019.
4 funds tracked by Wall St. Rank held PacWest Bancorp as of Q4 2023.

Based on TD Capital Management's 13F filing for Q4 2023, filed 12 Feb 2024.